Back

CMR layer-specific circumferential strain reveals subclinical cardiotoxicity undetected by guideline-concordant monitoring in sequential anthracycline and multi-agent HER2-directed therapy

28 August 2026 (13:39 - 13:51)
Organised by: Logo
Congress Presentation Part of: Seeing beyond the surface: cardiac magnetic resonance imaging in clinical cases Cardiac Magnetic Resonance (CMR) ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Nino Kavelashvili

Marienhospital, Gelsenkirchen (Germany)

4 More presentations in this session

Presentation thumbnail
Isolated left atrial myocarditis presenting with left atrial thrombus in a young woman: diagnosis by cardiac magnetic resonance
Associate Professor P. Zafirovska (Belgrade, RS)
Slides Video
Presentation thumbnail
The role of cardiac magnetic resonance in the diagnosis and management of postpartum choriocarcinoma with severe cardiopulmonary complications
Doctor N. Lutay (Lund, SE)
Slides Video
Presentation thumbnail
Palpitation unmasking a cardiac mass by CMR
Ms P. Bunditboondee (Bangkok, TH)
Slides Video
Presentation thumbnail
When the ventricle holds: conservative management of contained left ventricular rupture following STEMI
Doctor M. Khan (Wolverhampton, GB)
Slides Video

Access the full session

Session thumbnail
Seeing beyond the surface: cardiac magnetic resonance imaging in clinical cases
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 13:39 CET
You may be interested in
thumbnail
Congress Presentation
Case 2 - asymptomatic decline in global longitudinal strain during cancer therapy: what should guide our decisions
31 August 2026
thumbnail
Congress Presentation
Case 2 - new HFrEF: need cardiac magnetic resonance? When cardiac magnetic resonance changes diagnosis
30 August 2026
thumbnail
Congress Presentation
CMR as biomarker of cardiotoxicity: evidence-based for CMR in cardio-oncology
13 December 2025
thumbnail
Congress Presentation
Long-term cardiovascular outcomes after anthracycline and trastuzumab therapy in HER2-positive breast cancer: 5-year follow-up from the EMBRACE-MRI study
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources